erlotinib hydrochloride has been researched along with Hematuria in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Domoto, Y; Hirakawa, Y; Honda, K; Miyashita, N; Nagase, T; Nakamura, M; Nangaku, M; Oda, Y; Oki, R | 1 |
| Fettner, S; Ling, J; Lum, BL; Rakhit, A; Riek, M | 1 |
1 trial(s) available for erlotinib hydrochloride and Hematuria
| Article | Year |
|---|---|
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Topics: Administration, Oral; Adult; Aged; Algorithms; Area Under Curve; Creatine Kinase; Cross-Over Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fasting; Food-Drug Interactions; gamma-Glutamyltransferase; Glossitis; Hematuria; Humans; Liver; Male; Middle Aged; Molecular Structure; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
1 other study(ies) available for erlotinib hydrochloride and Hematuria
| Article | Year |
|---|---|
Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glomerulonephritis; Hematuria; Humans; Kidney; Lung; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteinuria | 2022 |